GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: ZYDG2 is an orally bioavailable free fatty acid receptor 1 (FFAR1; GPR40) agonist [1]. It is proposed for the treatment of type 2 diabetes, through activation of FFAR1 signalling in pancreatic β-cells. ZYDG2 is claimed to be devoid of the liver toxicity (via bile acid transporter inhibition) that led to the termination of fasiglifam clinical development.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Jain MR, Giri SR, Trivedi CJ, Bhoi BB, Rath AC, Rathod RM, Sundar R, Bandyopadhyay D, Ramdhave R, Patel GD et al.. (2025)
Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes. J Pharmacol Exp Ther, 392 (4): 103534. [PMID:40158321] |